Interprofessional approach to personalized medication management and therapy optimization in IBD care.
Ontology highlight
ABSTRACT: A considerable number of patients with chronic inflammatory bowel diseases (IBD) are required to manage extensive polypharmaceutical regimes, which significantly elevates the risk of drug-drug interactions. Also, the disease's impact often leads to the consumption of additional self-medication by the patients such as naturopathic remedies to alleviate disease-induced suffering and nutritional supplements to compensate for malabsorption syndromes inherent to the condition. There is a well-established consensus that polymedication coupled with unregulated supplementary intake can jeopardize the safety of drug therapy. Despite this, pharmaceutical co-supervision-proven to mitigate adverse drug events and enhance patient adherence to treatment-is generally lacking in routine clinical settings.
SUBMITTER: Fleischmann D
PROVIDER: S-EPMC11814462 | biostudies-literature | 2025
REPOSITORIES: biostudies-literature
ACCESS DATA